Merit Financial Group’s Myriad Genetics MYGN Stock Holding History

Merit Financial Group’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$110K	Buy	+19,242	New	+$87.3K	﹤0.01%	2211

Other funds holding MYGN

Assenagon Asset Management

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Wealth Enhancement Advisory Services

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

Impact Capital Partners Greenwood Village, Colorado $367M AUM 28.36% 1-Year Est. Return

State of Alaska Department of Revenue Juneau, Alaska $10.1B AUM 42.83% 1-Year Est. Return

True Wealth Design Akron, Ohio $420M AUM 22.7% 1-Year Est. Return

Physician Wealth Advisors Midvale, Utah $837M AUM 26% 1-Year Est. Return

Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return

GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Fortitude Family Office Scottsdale, Arizona $516M AUM 28.38% 1-Year Est. Return

Merit Financial Group's MYGN Position: Q2 2026 in Review

Merit Financial Group opened a new position in Myriad Genetics (MYGN) in Q2 2026: 19,242 shares worth $110K. The stake represents ﹤0.01% of the portfolio and ranks #2211 among its holdings.

16 funds tracked by Wall St. Rank hold MYGN as of Q2 2026.

Merit Financial Group held 19,242 shares of Myriad Genetics worth $110K as of Q2 2026.
Myriad Genetics was a new Merit Financial Group position in Q2 2026.
Myriad Genetics made up ﹤0.01% of Merit Financial Group's portfolio in Q2 2026, its #2211 holding.
16 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2026.

Based on Merit Financial Group's 13F filing for Q2 2026, filed 17 Jul 2026.